AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $559,178 | +32.1% | 45,985 | +36.5% | 0.00% | 0.0% |
| Q2 2023 | $423,272 | +13.3% | 33,700 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $373,733 | -9.2% | 33,700 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $411,477 | +14.3% | 33,700 | -2.3% | 0.00% | 0.0% |
| Q3 2022 | $360,000 | -0.6% | 34,506 | +2.4% | 0.00% | 0.0% |
| Q2 2022 | $362,000 | +13.5% | 33,700 | 0.0% | 0.00% | – |
| Q1 2022 | $319,000 | -18.0% | 33,700 | -0.0% | 0.00% | – |
| Q4 2021 | $389,000 | +20.8% | 33,704 | -0.1% | 0.00% | – |
| Q3 2021 | $322,000 | -0.9% | 33,741 | +0.1% | 0.00% | – |
| Q2 2021 | $325,000 | -2.4% | 33,700 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $333,000 | -60.2% | 33,700 | -6.9% | 0.00% | 0.0% |
| Q4 2020 | $836,000 | +54.2% | 36,206 | -5.6% | 0.00% | 0.0% |
| Q3 2020 | $542,000 | -7.5% | 38,363 | -1.3% | 0.00% | 0.0% |
| Q2 2020 | $586,000 | +65.5% | 38,857 | +1.3% | 0.00% | 0.0% |
| Q1 2020 | $354,000 | -5.3% | 38,363 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $374,000 | +64.8% | 38,363 | +20.4% | 0.00% | 0.0% |
| Q1 2017 | $227,000 | +41.9% | 31,850 | -0.9% | 0.00% | 0.0% |
| Q4 2016 | $160,000 | -32.2% | 32,154 | +1.0% | 0.00% | 0.0% |
| Q3 2016 | $236,000 | +35.6% | 31,850 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $174,000 | -35.3% | 31,850 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $269,000 | -12.9% | 31,850 | 0.0% | 0.00% | 0.0% |
| Q4 2015 | $309,000 | -30.7% | 31,850 | 0.0% | 0.00% | -50.0% |
| Q3 2015 | $446,000 | -1.1% | 31,850 | 0.0% | 0.00% | +100.0% |
| Q2 2015 | $451,000 | +30.0% | 31,850 | 0.0% | 0.00% | 0.0% |
| Q1 2015 | $347,000 | +30.9% | 31,850 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $265,000 | +39.5% | 31,850 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $190,000 | +79.2% | 31,850 | 0.0% | 0.00% | – |
| Q2 2014 | $106,000 | +60.6% | 31,850 | 0.0% | 0.00% | – |
| Q1 2014 | $66,000 | -12.0% | 31,850 | 0.0% | 0.00% | – |
| Q4 2013 | $75,000 | +1.4% | 31,850 | 0.0% | 0.00% | – |
| Q3 2013 | $74,000 | 0.0% | 31,850 | 0.0% | 0.00% | – |
| Q2 2013 | $74,000 | – | 31,850 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |